phase II study

You have access
A Phase II Study of Neoadjuvant Chemotherapy Followed by Extended Field Concurrent Chemoradiotherapy for Para-aortic Lymph Node Positive Cervical Cancer
YUKO SHIMOJI, YUTAKA NAGAI, TAKAFUMI TOITA, TAKURO ARIGA, JOICHI HEIANNA, TADAHARU NAKASONE, YUSUKE TAIRA, YOSHIHISA ARAKAKI, TOMOKO NAKAMOTO, TAKUMA OOYAMA, WATARU KUDAKA, ITOMI KANESHIMA, KUMIKO NISHIHIRA, KEIKO MEKARU and YOICHI AOKI

Anticancer Research June 2020, 40 (6) 3565-3570; DOI: https://doi.org/10.21873/anticanres.14346
You have access
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study
JOSEPH SGOUROS, GERASIMOS ARAVANTINOS, GEORGIA-ANGELIKI KOLIOU, GEORGE PENTHEROUDAKIS, FLORA ZAGOURI, AMANDA PSYRRI, DIMITRA IOANNA LAMPROPOULOU, STAMATINA DEMIRI, DIMITRIOS PECTASIDES, EVANGELIA RAZIS, GEORGE FOUNTZILAS and EPAMINONTAS SAMANTAS

Anticancer Research February 2020, 40 (2) 929-938; DOI: https://doi.org/10.21873/anticanres.14026
You have access
Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results
YUZURU NIIBE, TAKASHI ONDA, KEITARO MATSUO, YUSUKE INOUE and KAZUSHIGE HAYAKAWA

Anticancer Research December 2017, 37 (12) 6983-6988;
You have access
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer
SHIHO ARIMA, KYOKO SHIMIZU, TOMOYOSHI OKAMOTO, MASAO TOKI, YUTAKA SUZUKI, NAOHIRO OKANO, DAISUKE NARUGE, KIRIO KAWAI, TAKAAKI KOBAYASHI, AKIYOSHI KASUGA, HIROSHI KITAMURA, ATUKO TAKASU, FUMIO NAGASHIMA, MASANORI SUGIYAMA and JUNJI FURUSE

Anticancer Research February 2017, 37 (2) 909-914;
You have access
Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer
MASAHIRO YAMASAKI, ISAO MURAKAMI, KIKUO NAKANO, MIHOKO DOI, SOUICHI KITAGUCHI, TOMOHIRO KONDO, JOJI SAKURAI, NOBORU HATTORI and KEN-ICHI ARITA

Anticancer Research February 2017, 37 (2) 923-928;
You have access
Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
LEENA TIAINEN, MINNA TANNER, OUTI LAHDENPERÄ, PIA VIHINEN, ARJA JUKKOLA, PEETER KARIHTALA, NIINA PAUNU, TEPPO HUTTUNEN and PIRKKO-LIISA KELLOKUMPU-LEHTINEN

Anticancer Research December 2016, 36 (12) 6431-6438;
You have access
Bi-weekly Capecitabine–Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer –The PHOENiX Trial
TAKANORI MATSUI, NAOKI NAGATA, KEIJI HIRATA, SATOSHI OKAZAKI, SUMITO SATO, MASATO NAKAMURA, HOMIN KIM, KOJI OBA, JUNICHI SAKAMOTO and HIDEYUKI MISHIMA

Anticancer Research July 2016, 36 (7) 3437-3443;
You have access
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma
LORE DECOSTER, ISABELLE VANDE BROEK, BART NEYNS, FRANÇOISE MAJOIS, JEAN FRANÇOIS BAURAIN, SYLVIE ROTTEY, ANDRÉE RORIVE, ELLEN ANCKAERT, JOHAN DE MEY, SYLVIA DE BRAKELEER and JACQUES DE GRÈVE

Anticancer Research December 2015, 35 (12) 6893-6899;
You have access
Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer
ATSUSHI HORIIKE, NOBUYUKI YAMAMOTO, HISASHI TANAKA, NORIKO YANAGITANI, KEITA KUDO, FUMIYOSHI OHYANAGI, AKIRA ONO, TATEAKI NAITO, HARUYASU MURAKAMI, TAKESHI HORAI and MAKOTO NISHIO

Anticancer Research April 2014, 34 (4) 1975-1981;
You have access
Randomized Phase II Trial of S-1 plus Irinotecan Versus S-1 plus Paclitaxel as First-line Treatment for Advanced Gastric Cancer (OGSG0402)
NAOTOSHI SUGIMOTO, KAZUMASA FUJITANI, HIROSHI IMAMURA, NORIYA UEDO, SHOHEI IIJIMA, MOTOHIRO IMANO, TOSHIO SHIMOKAWA, YUKINORI KUROKAWA, HIROSHI FURUKAWA and MASAHIRO GOTO

Anticancer Research February 2014, 34 (2) 851-857;

Main menu

User menu

Search

phase II study

Pages